Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinsons disease: mechanisms of action
Novel therapies with precision mechanisms for type 2 diabetes mellitus
A previous Phase 2 trial in 255 patients with Parkinsons disease suggested pegsebrenatide may slow the progression of motor dysfunction, with the most pronounced effects in patients younger than 60
Potential implications of the new pharmacotherapies on obesity management The mean WL in clinical trials with the most efficacious new obesity pharmacotherapies ranges between 15% and 25% at 1 year (and it may be even higher for some agents that have not reached weight plateau at study completion)
US$ 27.63
US$ 23.14
US$ 24.78
US$ 29.43
US$ 27.74
US$ 24.49
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
US$ 21.05
